Skip to main content

Starling Oncology, Inc.

STLN
Exchange
Nasdaq
Industry
Services-Offices & Clinics of Doctors of Medicine
SEC CIK
0001799191

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.

Other share classesDFPHSTLNW

Q1 2022 vs. Q4 2021

How the institutions holding Starling Oncology, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of STLN: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders2129+8
Shares21.1M21.1M−30.8K (−0.1%)
Value$199.9M$159.0M−$40.9M (−20.5%)

New holders (10)

Institutions that held Starling Oncology, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to STLN in Q1 2022
InstitutionSharesValue% of portfolio
Millennium Management LLC159,823$1.14M0.00%
State Street Corp31,100$222.0K0.00%
First Republic Investment Management, Inc.18,300$130.0K0.00%
Northern Trust Corp18,065$129.0K0.00%
Balyasny Asset Management LLC10,873$78.0K0.00%
Bank of America Corp9,638$69.0K0.00%
Ovata Capital Management Ltd1,100$8.00K0.00%
State of Wyoming967$7.00K0.00%
Royal Bank of Canada579$4.00K0.00%
Wells Fargo & Company64$00.00%

Sold out (2)

Institutions that held Starling Oncology, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of STLN in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
CVI Holdings, LLC200,000$1.95M
UBS Group AG1,859$18.0K